From Breakthrough to Life: Engineered T-Cells, Patients, and the Future of Biotech
Wednesday, June 17, 2026 8:00 AM to 9:00 AM · 1 hr. (America/New_York)
TBD
00: Plenary05: PersonalizedMed-ComboProd-Diagnostics08: RegPolicy-Strategy-GlobalCollaboration18: Lift-Series
Information
Following a keynote presentation by Bruce Levine on the future of genetically engineered T-cells for human therapeutics, sit down with Bruce and Brad Watts for a fireside chat. Through scientific, policy, and patient lenses, the session will examine what it takes to translate high-risk science into sustainable therapies, and what that implies for regulators, payers, sponsors, and technology partners.
Session Level
Intermediate
Featured Topics
Biotech-ClinTech-PathwayStudent and Early Career PathwayTherapeutic Pathways
Learning Objectives
Describe how advances in engineered T-cells, including CAR-T, are reshaping expectations for cancer treatment and the broader pipeline; Identify scientific, regulatory, and system conditions needed to translate high-risk engineered innovations into equitable, scalable patient benefit; Discuss how real patient and family experiences inform future strategies for regulators, payers, sponsors, researchers, and technology partners developing next-generation cell therapies.
Speakers
Katie Truong
SVP & Managing Director, DIA Americas and Global Head of Business OperationsDIA
Bradley Watts
Patient/Industry Advocate and Vice President, Business Development ExecutiveEmily Whitehead Foundation and Conner Strong & Buckelew
Bruce Levine
Barabara and Edward Netter Professor in Cancer Gene TherapyPerelman School of Medicine at the University of PennsylvaniaDocuments & Links
Understanding Pharmacoepidemiology and Real-World Evidence Studies